3 results
Approved WMOCompleted
The key objective of this study is to assess next-day residual effects of MK-4305 (20 and 40 mg) via driving performance after 1 day of dosing and after 8 days of dosing.
Approved WMOSuspended
To determine the performance (safety and effectiveness) of miniaturo*-I for the treatment of urinary urge incontinence.
Approved WMOCompleted
Primary objective: The primary objective of this study is to investigate if taking methenamine hippurate reduce the need for antibiotic usage due to recurrent UTI (measured as the number of courses of antibiotics).Secondary objectives:to investigate…